The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: A comparative study

Differentiating reactive mesothelial (RM) proliferation from malignant mesothelioma (MM) can be cytologically challenging. There have been discordant studies reporting the value of epithelial membrane antigen (EMA) in differentiating RM from MM. In this study, we investigated the expression of two different clones of EMA in RM and MM. Twenty cases of pleural effusion smears of RM and 20 cases of MM with their corresponding cell blocks were retrieved from the hospital computer system. Diagnosis of MM was confirmed by surgical decortication or pneumonectomy with immunostaining studies and/or electron microscopy. Cases of RM were confirmed by clinical history and histology. Cell blocks were formalin‐fixed, paraffin‐embedded, and immunostained for EMA clone Mc5 and EMA clone E29. The positive rates for clone Mc5 were 14/20 (70%) for MM and 12/20 (60%) for RM and EMA clone E29 were 15/20 (75%) for MM and 0/20 (0%) for RM. The sensitivity and specificity for EMA clone Mc5 were 70 and 40%, respectively. For EMA clone E29, the sensitivity and specificity were 75 and 100%, respectively. In conclusion, both RM and MM immunostained for EMA clone Mc5, indicating that it is not a reliable immunocytochemical marker for differentiating RM from MM. EMA clone E29 was negative in all cases of RM and positive in 75% of MM and therefore is a reliable immunocytochemical marker for differentiating RM from MM. Diagn. Cytopathol. 2005;32:156–159. © 2005 Wiley‐Liss, Inc.

[1]  H. Battifora,et al.  Immunocytochemical profile of benign and carcinomatous effusions. A practical approach to difficult diagnosis. , 1990, American journal of clinical pathology.

[2]  J. Silverman,et al.  Significance of epithelial membrane antigen in the work‐up of problematic serous effusions , 1995, Diagnostic cytopathology.

[3]  C. Parker,et al.  Lung cancer • 8: Management of malignant mesothelioma , 2003, Thorax.

[4]  M. McNutt,et al.  Reactive and Neoplastic Serosal Tissue: A Light-Microscopic, Ultrastructural, and Immunocytochemical Study , 1986, The American journal of surgical pathology.

[5]  D. Whitaker.  Invited review The cytology of malignant mesothelioma , 2000 .

[6]  P. Devine,et al.  Markers for metastatic adenocarcinoma in serous effusion specimens , 1994, Diagnostic cytopathology.

[7]  G. Falconieri,et al.  Cytopathology of malignant mesothelioma: A study of its patterns and histological bases , 1993, Diagnostic cytopathology.

[8]  A. Berner,et al.  The Role of Desmin and N-Cadherin in Effusion Cytology: A Comparative Study Using Established Markers of Mesothelial and Epithelial Cells , 2001, The American journal of surgical pathology.

[9]  T. H. van der Kwast,et al.  Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions , 1997, Diagnostic cytopathology.

[10]  M. C. Lee,et al.  Immunohistochemical panel for distinguishing between carcinoma and reactive mesothelial cells in serious effusions. , 1996, Acta cytologica.

[11]  C. Cohen,et al.  Distinction between carcinoma cells and mesothelial cells in serous effusions. Usefulness of immunohistochemistry. , 1990, Acta cytologica.

[12]  Paul J. Kurtin,et al.  Epithelial membrane antigen--a diagnostic discriminant in surgical pathology: immunohistochemical profile in epithelial, mesenchymal, and hematopoietic neoplasms using paraffin sections and monoclonal antibodies. , 1985, Human pathology.

[13]  J. Sloane,et al.  Distribution of epithelial membrane antigen in normal and neoplastic tissues and its value in diagnostic tumor pathology , 1981, Cancer.

[14]  D. Henderson,et al.  The concept of mesothelioma in situ: implications for diagnosis and histogenesis. , 1992, Seminars in diagnostic pathology.

[15]  K. Metze,et al.  The use of epithelial membrane antigen and silver‐stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses , 1998, Cancer.

[16]  R. Attanoos,et al.  The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet‐derived growth factor‐receptor, P‐glycoprotein and Bcl‐2 , 2003, Histopathology.

[17]  E. Heyderman,et al.  A new antigen on the epithelial membrane: its immunoperoxidase localisation in normal and neoplastic tissue. , 1979, Journal of clinical pathology.

[18]  A. Renshaw,et al.  The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. , 1997, Chest.

[19]  J. Said,et al.  Epithelial membrane antigen in the cytodiagnosis of effusions and aspirates: Immunocytochemical and ultrastructural localization in benign and malignant cells , 1987, Diagnostic cytopathology.

[20]  A. Leong,et al.  “Thick” cell membranes revealed by immunocytochemical staining: A clue to the diagnosis of mesothelioma , 1990, Diagnostic cytopathology.

[21]  W. Travis,et al.  The separation of benign and malignant mesothelial proliferations. , 2000, The American journal of surgical pathology.

[22]  D. Weaver,et al.  c-Kit expression in desmoid fibromatosis. Comparative immunohistochemical evaluation of two commercial antibodies. , 2003, American journal of clinical pathology.

[23]  P. Johansen,et al.  Immunocytochemical staining of smears and corresponding cell blocks from serous effusions: A follow‐up and comparative investigation , 1996, Diagnostic cytopathology.

[24]  D. Henderson,et al.  Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review. , 1998, American journal of clinical pathology.

[25]  P. Cagle,et al.  p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens. , 1994, Human pathology.

[26]  N. Ordóñez.  The Immunohistochemical Diagnosis of Mesothelioma: A Comparative Study of Epithelioid Mesothelioma and Lung Adenocarcinoma , 2003, The American journal of surgical pathology.

[27]  A. Hjerpe,et al.  Immunohistochemical differences between hyaluronan- and non-hyaluronan-producing malignant mesothelioma , 1997 .

[28]  J. Stoop,et al.  Identification of Malignant Cells In Serous Effusions Using A Panel of Monoclonal Antibodies Ber‐Ep4, Mca‐B‐12 and Ema , 1992, Cytopathology : official journal of the British Society for Clinical Cytology.